PECAM1 and neoplasm: The therapy also reduced levels of p-STAT3 and STAT3 in the TME, decreased the density of α-smooth muscle actin (α-SMA) and CD31 markers, and further increased CD8+ T-cell infiltration, collectively contributing to reduced tumor size, enhanced tumor cell apoptosis, and inhibited tumor growth [277].